Investing.com - Purple Biotech ADR (NASDAQ: PPBT) reported fourth quarter EPS of $-0.190, in line with the analyst estimate of $-0.190. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Purple Biotech ADR's stock price closed at $0.830. It is down -25.230% in the last 3 months and down -62.780% in the last 12 months.
Purple Biotech ADR saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Purple Biotech ADR's stock price’s past reactions to earnings here.
According to InvestingPro, Purple Biotech ADR's Financial Health score is "fair performance".
Check out Purple Biotech ADR's recent earnings performance, and Purple Biotech ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar